The preclinical data demonstrate that adavosertib inhibits the G2 cell cycle checkpoint and renders p53-deficient tumor cells vulnerable to radiation and DNA-damaging chemotherapies [127, 128]. This evidence concerns the gene TP53 and neoplasm.